{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:38:38Z","timestamp":1785001118654,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82500241"],"award-info":[{"award-number":["82500241"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32571705"],"award-info":[{"award-number":["32571705"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the special fund of the National Clinical Key Specialty Construction Program, P. R. China","award":["2023"],"award-info":[{"award-number":["2023"]}]},{"name":"Beijing Municipal Natural Science Foundation","award":["7232202"],"award-info":[{"award-number":["7232202"]}]},{"name":"Beijing Municipal Health Commission, Capital's Funds for Health Improvement and Research","award":["2024-2-4096"],"award-info":[{"award-number":["2024-2-4096"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06926-0","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:11:30Z","timestamp":1773040290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inhibition of CDC20 suppresses the development and progression of mantle cell lymphoma through PI3K\/AKT pathway"],"prefix":"10.1007","volume":"105","author":[{"given":"Yingtong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuozi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"6926_CR1","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14728222.2020.1813718","volume":"24","author":"P Klener","year":"2020","unstructured":"Klener P (2020) Mantle cell lymphoma: insights into therapeutic targets at the preclinical level. Expert Opin Ther Targets 24:1029\u20131045","journal-title":"Expert Opin Ther Targets"},{"key":"6926_CR2","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajh.25487","volume":"94","author":"P Jain","year":"2019","unstructured":"Jain P, Wang M (2019) Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol 94:710\u2013725","journal-title":"Am J Hematol"},{"key":"6926_CR3","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","volume":"132","author":"K Maddocks","year":"2018","unstructured":"Maddocks K (2018) Update on mantle cell lymphoma. Blood 132:1647\u20131656","journal-title":"Blood"},{"issue":"Suppl 1","key":"6926_CR4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hon.3149","volume":"41","author":"E Silkenstedt","year":"2023","unstructured":"Silkenstedt E, Dreyling M (2023) Mantle cell lymphoma-update on molecular biology, prognostication and treatment approaches. Hematol Oncol 41(Suppl 1):36\u201342","journal-title":"Hematol Oncol"},{"key":"6926_CR5","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","volume":"26","author":"Y Song","year":"2020","unstructured":"Song Y, Zhou K, Zou D et al (2020) Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton\u2019s tyrosine kinase. Clin Cancer Res 26:4216\u20134224","journal-title":"Clin Cancer Res"},{"key":"6926_CR6","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF et al (2017) Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol 35:826\u2013833","journal-title":"J Clin Oncol"},{"key":"6926_CR7","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1200\/JCO.2005.05.019","volume":"23","author":"V Fern\u00e0ndez","year":"2005","unstructured":"Fern\u00e0ndez V, Hartmann E, Ott G et al (2005) Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 23:6364\u20139","journal-title":"J Clin Oncol"},{"key":"6926_CR8","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.hoc.2020.05.003","volume":"34","author":"K Wang","year":"2020","unstructured":"Wang K, Huang X, Di Liberto M et al (2020) Cell cycle dysregulation in mantle cell lymphoma: genomics and therapy. Hematol Oncol Clin North Am 34:809\u2013823","journal-title":"Hematol Oncol Clin North Am"},{"key":"6926_CR9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/cdd.2011.197","volume":"19","author":"E Manchado","year":"2012","unstructured":"Manchado E, Guillamot M, Malumbres M (2012) Killing cells by targeting mitosis. Cell Death Differ 19:369\u2013377","journal-title":"Cell Death Differ"},{"key":"6926_CR10","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1021\/acs.jmedchem.9b02097","volume":"63","author":"P Huang","year":"2020","unstructured":"Huang P, Le X, Huang F et al (2020) Discovery of a dual tubulin polymerization and cell division cycle 20 homologue inhibitor via structural modification on apcin. J Med Chem 63:4685\u20134700","journal-title":"J Med Chem"},{"key":"6926_CR11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/jso.23109","volume":"106","author":"T Kato","year":"2012","unstructured":"Kato T, Daigo Y, Aragaki M et al (2012) Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients. J Surg Oncol 106:423\u201330","journal-title":"J Surg Oncol"},{"key":"6926_CR12","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3892\/ijo.2014.2559","volume":"45","author":"J Li","year":"2014","unstructured":"Li J, Gao JZ, Du JL et al (2014) Increased CDC20 expression is associated with development and progression of hepatocellular carcinoma. Int J Oncol 45:1547\u20131555","journal-title":"Int J Oncol"},{"key":"6926_CR13","first-page":"722","volume":"7","author":"ZY Ding","year":"2014","unstructured":"Ding ZY, Wu HR, Zhang JM et al (2014) Expression characteristics of CDC20 in gastric cancer and its correlation with poor prognosis. Int J Clin Exp Pathol 7:722\u2013727","journal-title":"Int J Clin Exp Pathol"},{"key":"6926_CR14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1479-5876-11-142","volume":"11","author":"WJ Wu","year":"2013","unstructured":"Wu WJ, Hu KS, Wang DS et al (2013) CDC20 overexpression predicts a poor prognosis for patients with colorectal cancer. J Transl Med 11:142","journal-title":"J Transl Med"},{"key":"6926_CR15","doi-asserted-by":"crossref","DOI":"10.1186\/1756-8722-5-15","volume":"5","author":"DZ Chang","year":"2012","unstructured":"Chang DZ, Ma Y, Ji B et al (2012) Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol 5:15","journal-title":"J Hematol Oncol"},{"key":"6926_CR16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00428-013-1473-6","volume":"463","author":"JW Choi","year":"2013","unstructured":"Choi JW, Kim Y, Lee JH et al (2013) High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer. Virchows Arch 463:681\u20137","journal-title":"Virchows Arch"},{"key":"6926_CR17","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1038\/bjc.2014.252","volume":"110","author":"H Karra","year":"2014","unstructured":"Karra H, Repo H, Ahonen I et al (2014) Cdc20 and securin overexpression predict short-term breast cancer survival. Br J Cancer 110:2905\u201313","journal-title":"Br J Cancer"},{"key":"6926_CR18","doi-asserted-by":"crossref","first-page":"10475","DOI":"10.2147\/OTT.S253758","volume":"13","author":"C Sun","year":"2020","unstructured":"Sun C, Li M, Feng Y et al (2020) MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma. Onco Targets Ther 13:10475\u201310487","journal-title":"Onco Targets Ther"},{"key":"6926_CR19","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.18632\/oncotarget.6768","volume":"7","author":"S Lub","year":"2016","unstructured":"Lub S, Maes A, Maes K et al (2016) Inhibiting the anaphase promoting complex\/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells. Oncotarget 7:4062\u20134076","journal-title":"Oncotarget"},{"key":"6926_CR20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/jop.12115","volume":"43","author":"IM Moura","year":"2014","unstructured":"Moura IM, Delgado ML, Silva PM et al (2014) High CDC20 expression is associated with poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med 43:225\u2013231","journal-title":"J Oral Pathol Med"},{"key":"6926_CR21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/ijc.21902","volume":"119","author":"V Ouellet","year":"2006","unstructured":"Ouellet V, Guyot MC, Le Page C et al (2006) Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 119:599\u2013607","journal-title":"Int J Cancer"},{"key":"6926_CR22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00428-008-0685-7","volume":"453","author":"G Marucci","year":"2008","unstructured":"Marucci G, Morandi L, Magrini E et al (2008) Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. Virchows Arch 453:599\u2013609","journal-title":"Virchows Arch"},{"key":"6926_CR23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40164-023-00381-7","volume":"12","author":"Y Chen","year":"2023","unstructured":"Chen Y, Yang P, Wang J et al (2023) p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma. Exp Hematol Oncol 12:28","journal-title":"Exp Hematol Oncol"},{"key":"6926_CR24","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/07853890.2014.912836","volume":"46","author":"M Martini","year":"2014","unstructured":"Martini M, De Santis MC, Braccini L et al (2014) PI3K\/AKT signaling pathway and cancer: an updated review. Ann Med 46:372\u201383","journal-title":"Ann Med"},{"key":"6926_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26051868","author":"MA Rahman","year":"2025","unstructured":"Rahman MA, Jalouli M, Bhajan SK et al (2025) A comprehensive review of nanoparticle-based drug delivery for modulating PI3K\/AKT\/mTOR-mediated autophagy in cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26051868","journal-title":"Int J Mol Sci"},{"key":"6926_CR26","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1161\/01.CIR.0000053443.27512.33","volume":"107","author":"B Rondelet","year":"2003","unstructured":"Rondelet B, Kerbaul F, Motte S et al (2003) Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation 107:1329\u20131335","journal-title":"Circulation"},{"key":"6926_CR27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","volume":"17","author":"T Otto","year":"2017","unstructured":"Otto T, Sicinski P (2017) Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer 17:93\u2013115","journal-title":"Nat Rev Cancer"},{"key":"6926_CR28","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1080\/10428194.2016.1248965","volume":"58","author":"N Vogt","year":"2017","unstructured":"Vogt N, Dai B, Erdmann T et al (2017) The molecular pathogenesis of mantle cell lymphoma. Leuk Lymphoma 58:1530\u20131537","journal-title":"Leuk Lymphoma"},{"key":"6926_CR29","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","volume":"119","author":"JP Leonard","year":"2012","unstructured":"Leonard JP, LaCasce AS, Smith MR et al (2012) Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 119:4597\u2013607","journal-title":"Blood"},{"key":"6926_CR30","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1080\/10428194.2019.1612062","volume":"60","author":"P Martin","year":"2019","unstructured":"Martin P, Ruan J, Furman R et al (2019) A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Leuk Lymphoma 60:2917\u20132921","journal-title":"Leuk Lymphoma"},{"key":"6926_CR31","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","volume":"133","author":"P Martin","year":"2019","unstructured":"Martin P, Bartlett NL, Blum KA et al (2019) A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood 133:1201\u20131204","journal-title":"Blood"},{"key":"6926_CR32","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3324\/haematol.2019.224535","volume":"106","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser F, Bouabdallah K, Stilgenbauer S et al (2021) Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study. Haematologica 106:859\u2013862","journal-title":"Haematologica"},{"key":"6926_CR33","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1080\/10428194.2016.1239259","volume":"58","author":"MD Seftel","year":"2017","unstructured":"Seftel MD, Kuruvilla J, Kouroukis T et al (2017) The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. Leuk Lymphoma 58:1358\u20131365","journal-title":"Leuk Lymphoma"},{"key":"6926_CR34","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/JCO.2003.09.057","volume":"21","author":"CT Kouroukis","year":"2003","unstructured":"Kouroukis CT, Belch A, Crump M et al (2003) Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:1740\u20131745","journal-title":"J Clin Oncol"},{"key":"6926_CR35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pharmthera.2015.04.002","volume":"151","author":"L Wang","year":"2015","unstructured":"Wang L, Zhang J, Wan L et al (2015) Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacol Ther 151:141\u201351","journal-title":"Pharmacol Ther"},{"key":"6926_CR36","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.devcel.2014.04.022","volume":"29","author":"L Wan","year":"2014","unstructured":"Wan L, Tan M, Yang J et al (2014) APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction. Dev Cell 29:377\u2013391","journal-title":"Dev Cell"},{"key":"6926_CR37","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.2174\/1381612811319180005","volume":"19","author":"Z Wang","year":"2013","unstructured":"Wang Z, Wan L, Zhong J et al (2013) Cdc20: a potential novel therapeutic target for cancer treatment. Curr Pharm Des 19:3210\u20133214","journal-title":"Curr Pharm Des"},{"key":"6926_CR38","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/s41416-019-0471-0","volume":"120","author":"A Maes","year":"2019","unstructured":"Maes A, Maes K, De Raeve H et al (2019) The anaphase-promoting complex\/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma. Br J Cancer 120:1137\u20131146","journal-title":"Br J Cancer"},{"key":"6926_CR39","doi-asserted-by":"crossref","first-page":"e8843","DOI":"10.7717\/peerj.8843","volume":"8","author":"D Guo","year":"2020","unstructured":"Guo D, Wang H, Sun L et al (2020) Identification of key gene modules and hub genes of human mantle cell lymphoma by coexpression network analysis. PeerJ 8:e8843","journal-title":"PeerJ"},{"key":"6926_CR40","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","volume":"108","author":"M Rudelius","year":"2006","unstructured":"Rudelius M, Pittaluga S, Nishizuka S et al (2006) Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 108:1668\u201376","journal-title":"Blood"},{"key":"6926_CR41","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","volume":"111","author":"J Dal Col","year":"2008","unstructured":"Dal Col J, Zancai P, Terrin L et al (2008) Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 111:5142\u201351","journal-title":"Blood"},{"key":"6926_CR42","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2141.2005.05630.x","volume":"130","author":"EG Rizzatti","year":"2005","unstructured":"Rizzatti EG, Falc\u00e3o RP, Panepucci RA et al (2005) Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br J Haematol 130:516\u201326","journal-title":"Br J Haematol"},{"key":"6926_CR43","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2013.15","volume":"3","author":"M Reis-Sobreiro","year":"2013","unstructured":"Reis-Sobreiro M, Rou\u00e9 G, Moros A et al (2013) Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma. Blood Cancer J 3:e118","journal-title":"Blood Cancer J"},{"key":"6926_CR44","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.beha.2012.04.008","volume":"25","author":"SM Smith","year":"2012","unstructured":"Smith SM (2012) Targeting mTOR in mantle cell lymphoma: current and future directions. Best Pract Res Clin Haematol 25:175\u2013183","journal-title":"Best Pract Res Clin Haematol"},{"key":"6926_CR45","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/abbs\/gmy070","volume":"50","author":"D Yu","year":"2018","unstructured":"Yu D, Zhang Y, Chen G et al (2018) Targeting the PI3K\/Akt\/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression. Acta Biochim Biophys Sin (Shanghai) 50:782\u2013792","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"6926_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178132","author":"N Maher","year":"2025","unstructured":"Maher N, Maiellaro F, Ghanej J et al (2025) Unraveling the epigenetic landscape of mature B cell neoplasia: mechanisms, biomarkers, and therapeutic opportunities. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26178132","journal-title":"Int J Mol Sci"},{"key":"6926_CR47","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1038\/s41598-020-59365-w","volume":"10","author":"J Wang","year":"2020","unstructured":"Wang J, He N, Wang R et al (2020) Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia. Sci Rep 10:2706","journal-title":"Sci Rep"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06926-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06926-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06926-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:59:45Z","timestamp":1776405585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06926-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6926"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06926-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7114313\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}